- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Silver47 Exploration
Purpose Bitcoin ETF
Fidelity Advantage Bitcoin ETF
Jindalee Lithium
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
VIDEO–Chris Wagner of Emerald Health Therapeutics on the impact of the Canadian Marijuana Industry at a Global Scale
The Investing News Network had the opportunity to speak with Chris Wagner, CEO of Emerald Health Therapeutics about how Canada’s framework for legalization will be impactful at a global scale and what the company will do to meet with rising demand of cannabis once legalization is in effect.
There’s no better time than now to be in the Canadian marijuana industry.
With legalization slated for summer 2018, interest in the sector is hotter than ever– at a Canadian level but also at a global scale–as recreational legalization will no doubt impact the framework for other countries looking to make similar steps moving forward.
On that note, at the CanTech Investment Conference in Toronto on January 31, the Investing News Network (INN) had the opportunity to speak with Chris Wagner, CEO of Emerald Health Therapeutics (TSXV:EMH) to discuss how Canada’s framework for legalization will be impactful at a global scale. Wagner said that Canadian companies, including ones like Emerald Health, are developing new cannabis products that are useful not just for Canadians, but for people all around the world.
“We’re creating new formulations, new ways of delivering cannabis, new products … and exporting those around the world,” Wagner said.
Similarly, when legalization in Canada comes to fruition in a few months, demand will, unsurprisingly, increase. For Emerald Health, Wagner said the company has already been supplying medical cannabis to its patients for over four years, so he said the company knows “exactly what people want.”
“We’re preparing for the adult-use market by converting large-scale greenhouses … into cannabis-growing facilities,” he said. “This one million square foot greenhouse facility will be able to produce 750,000 kilograms of cannabis.”
In addition to officially preparing for legalization to come into full swing, Wagner also spoke about Emerald Health’s joint venture with DMG Blockchain, called CannaChain, and the impact blockchain will have on the cannabis industry.
To watch the interview, scroll to the top of the article for more of what Wagner had to say.
Don’t forget to follow us @INN_Technology for real-time news updates!
Securities Disclosure: I, Jocelyn Aspa, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.